Second International Conference on Cancer Vaccines/Adjuvants/Delivery for the Next Decade (CVADD): Heidelberg, Germany, 10-12 October 2007

PMID: 18270701
Journal: Cancer immunology, immunotherapy : CII (volume: 57, issue: 9, Cancer Immunol. Immunother. 2008 Sep;57(9):1421-7)
Published: 2008-02-13

Authors:
Schirrmacher V, Beckhove P, Fournier P, Umansky V

ABSTRACT

Open in PubMed

Das könnte Dich auch interessieren
Antitumor effects of Newcastle Disease Virus in vivo: local versus systemic effects
An effective tumor vaccine optimized for costimulation via bispecific and trispecific fusion proteins
Targeting of IL-2 and GM-CSF immunocytokines to a tumor vaccine leads to increased anti-tumor activity
Synergy between TMZ and individualized multimodal immunotherapy to improve overall survival of IDH1 wild-type MGMT promoter-unmethylated GBM patients
Strong T‑cell costimulation can reactivate tumor antigen‑specific T cells in late‑stage metastasized colorectal carcinoma patients: results from a phase Ⅰ clinical study
Detection and functional analysis of tumor infiltrating T-lymphocytes (TIL) in liver metastases from colorectal cancer